The real residual risk in patients with CVD & diabetes: The promise of epigenetics
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- LDL-c: Done Deal, Next Epigenetics?A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
Prof Kausik Ray
- LDL-c: Done Deal, Next Epigenetics?Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
Jorge Plutzky, MD
